EC approves BMS melanoma drug Opdivo two and four-week flat dosing schedule

This article was originally published here

The FDA has approved Opdivo flat dosing schedule of 240 mg infused over 30 minutes every two weeks (Q2W) or 480 mg infused over 60 minutes every four

The post EC approves BMS melanoma drug Opdivo two and four-week flat dosing schedule appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply